The most effective natural Osteoporosis treatment
Click on a box to see what we consider
the most effective natural Osteoporosis treatment for you

WOMEN 39
AND UNDER		 MEN 39
AND UNDER		 WOMEN 40
AND UP		 MEN 40
AND UP
click here...click here...click here...click here...

What is Osteoporosis?

More than 200 million people worldwide are affected by osteoporosis, a bone disease characerised by the progressive thinning of bone tissue and loss of bone density. This leads to an increased risk of fractures, particularly of the hip, spine and wrist. Approximately one in three women and one in eight men will suffer from a fracture due to osteoporosis. From the age of 30, men and women start to lose bone tissue; men lose about one-half percent of total bone tissue per year and women lose around one percent per year. Surrounding the time of menopause, some women can lose up to six percent of their total bone tissue in one year.

Our bones are made up of collagen, calcium and other minerals, which together help keep them strong and flexible. Throughout our lives old, damaged bone is removed by specialised cells called osteoclasts and replaced with new bone by cells called osteoblasts. In childhood and teenage years, new bone formation happens at a faster pace than old bone being broken down resulting in increased bone density and strength. However – due to the natural process of aging – after the age of 30, bone deterioration slowly begins to exceed bone formation, leading to the typical loss of bone density seen in osteoporosis.

Many factors increase your risk of developing osteoporosis including insufficient intake of calcium, vitamin D3, vitamin K2, vitamin C, vitamin B12, vitamin B6, Magnesium, silicon and boron and zinc from your diet.

Conventional osteoporosis pharmaceutical drug treatment may cause significant side effects. The ideal treatment should treat the cause of the problem by simply supplying your body with sufficient amounts of the substances that are vital for bone health and growth. Bone density scanning demonstrates that certain natural nutritional supplements are able to increase bone mass significantly in just one to two years without any negative side effects (see below).

Which natural ingredients can have an effect on osteoporosis?

Calcium, vitamins D3, K2, B6, B12, C and magnesium, silicon, boron, zinc, copper, and docosahexaenoic acid (omega-3).

What effects do these ingredients have?

  • Increase bone density.
  • Reduce risk of fractures.
  • Maintain healthy bones and joint function.
  • Increase muscle power and strength.

For the reader with a deeper interest:

How do these ingredients work?

  • Treat and prevent vitamin and mineral deficiencies.
  • Increase bone density by increasing natural osteoblast (bone formation) activity.
  • Inhibit osteoclast activity (breaking down of bone).
  • Vitamin D maintains normal blood levels of calcium and phosphorous and helps in the absorption of calcium.
  • Boron increases calcium uptake.
  • Ingredients work together in bone metabolism, growth and development.
  • Deliver the "building blocks" to re-establish bone structure.
  • Counteract oxidative stress, which contributes to bone deterioration.
  • Enhance the effect of oestrogen in women, which has beneficial effects on bone health.

The information above is based on more than 12,000 articles published in scientific journals and which are available at MEDLINE, the world's largest medical database. Below you will find a few of them listed:

References

  1. Adami S. Protelos: Nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Bone. 2006 Feb;38(2 Suppl 1):23–7.
  2. Ali M, Afzal M, Gubler CJ, Burka JF. A potent thromboxane formation inhibitor in green tea leaves. Prostaglandins Leukot Essent Fatty Acids 40:281-283; 1990.
  3. Atik OS, Uslu MM, et al. Etiology of senile osteoporosis: A hypothesis. Clin Orthop Relat Res. 2006 Feb;443:25–7.
  4. Bertone-Johnson, E. & all. “Calcium and vitamin D intake and risk of incident premenstrual syndrome.” Archives of Internal Medicine, June 13, 2005.
  5. Bestul MB, McCollum M, et al. Impact of the Women’s Health Initiative trial results on hormone replacement therapy. Pharmacotherapy. 2004 Apr;24(4):495–9.
  6. Bushnell CD. Hormone replacement therapy and stroke: The current state of knowledge and directions for future research. Semin Neurol. 2006 Mar;26(1):123–30.
  7. Buvat, J. Androgen therapy with dehydroepiadrosterone. World Urol. 2003 Nov;21(5):346–55.
  8. Cardinali DP, Ladizesky MG, et al. Melatonin effects on bone: Experimental facts and clinical perspective. J Pineal Res. 2003 Mar;34(2):81–7.
  9. Castelo-Branco C. Management of osteoporosis: An overview. Drugs Aging 1998;12(Supp1.1):25–32.
  10. Center JR, Nguyen TV, et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Cli Endocrinol Metab. 1999 Oct;84(10):3626–35.
  11. Cetin A, Gokce-Kutsal Y, et al. Predictors of bone mineral density in healthy males. Rheumatol Int. 2001 Nov;21(3):85–8.
  12. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses’ Health Study. Am J Epidemiol. 2000 Nov 15;152(10):950–64.
  13. Conconi MT, Tommasini M, et al. Essential amino acids increase the growth and alkaline phosphatase activity in osteoblasts cultured in vivo. Farmaco. 2001 Oct;56(10):755–61.
  14. Eisinger, J. & all. “Effects of silicon, fluoride, etidronate and magnesiliconum on bone mineral density: A retrospective study.” 1993.
  15. Feskanich D, Weber P, et al. Vitamin K intake and hip fractures in women: A prospective study. Am J Clin Nutr. 1999 Jan;69(1):74–9.
  16. Fleisch HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med. 1997;29:55–62.
  17. Fontana A, Delmas PD. Clinical use of selective estrogen receptor modulators. Curr Opin Rheumatol. 2001 Jul;13(4):333–9.
  18. Fraunfelder FW, Fraunfelder FT, et al. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Opthalmol. 2003 Feb;135(2):219–21.
  19. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug Induced Ocular Side Effects. Ophthalmology. 2004 Jul;111(7):1275–9.
  20. Gjesdal CG, Vollset SE, et al. Plasma total homocysteine level and bone mineral density: The Hordaland Homocysteine Study. Arch Intern Med. 2006 Jan 9;166(1):88–94.
  21. Gonzalez-Reimers E, Duran-Castellon MC, et al. Effect of zinc supplementation on ethanol-mediated bone alterations. Food Chem Toxicol. 2005 Oct;43(10):1497–505.
  22. Greenspan SL, Harris ST, et al. Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician. 2000;61:2731–6.
  23. Gurlek A, Gedik O. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover. J Endocrinol Invest. 2001 Jun;24(6):408-14.
  24. Hall SL, Greendale GA. The relation of dietary vitamin C intake to bone mineral density: Results from the PEPI study. Calcif Tissue Int. 1998 Sep;63(3):183–9.
  25. Hein G, Weiss C, et al. Advanced glycation end product modification of bone proteins and bone remodelling: Hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis. 2006 Jan;65(1):101–4.
  26. Herrmann M, Widmann T, et al. Homocysteine: A newly recognised risk factor for osteoporosis. Clin Chem Lab Med. 2005;43(10):1111–7.
  27. Hirota T, Hirota K. [Osteoporosis and intake of vitamins]. Clin Calcium. 2005 May;15(5):854–7.
  28. Hodges SJ, Pilkington MJ, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone. 1991;12(6):387–9.
  29. Jugdaohsing, R. & all. “Long-term evaluation of blood silicon and osteocalcin in operatively treated patients with benign tumours using bioactive glass and autogenous bone.” Journal of Biomedical Materials Research. 2007.
  30. Kanis JA, Oden A, et al. Excess mortality after hospitalization for vertebral fractures. Osteoporos Int. 2004 Feb;15(2):108–12.
  31. Kasper DL, Braunwald E, et al. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill Medical Publishing Division; 2005.
  32. Katsuyama H, Sunami S, et al. [Influence of nutrients intake on bone turnover markers]. Clin Calcium. 2005 Sep;15(9):1529–34.
  33. Kawaura A, Nishida Y, et al. [Phosphorus intake and bone mineral density (BMD)]. Clin Calcium. 2005 Sep;15(9):1501–6.
  34. Klevay LM, Wildman RE. Meat diets and fragile bones: Inferences about osteoporosis. J Trace Elem Med Biol. 2002;16(3):149–54.
  35. Knapen MH, Hamulyak K, et al. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med. 1989 Dec 15;111(12):1001–5.
  36. Knapen MH, Jie KS, et al. Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. Calcif Tissue Int. 1993 Aug;53(2):81–5.
  37. LaCroix AZ. Estrogen with and without progestin: Benefits and risks of short-term use. Am J Med. 2005 Dec 19;118(12 Suppl 2):79–87.
  38. Knapen, M.H.J. & all. “Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women.” Osteoporosis International. 2009.
  39. Legrain S, Girard L. Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects. Drugs Ageing 2003;20(13):949–67.
  40. Liang M, Liao EY. [Effects of progestin on proliferation and differentiation of osteoblasts]. Zhonghua Fu Chan Ke Za Zhi. 2004 Apr;39(4):250–3.
  41. Lips, P. & all. ”High prevalence of vitamin D inadequacy among community dwelling postmenopausal women with osteporosis.” Presented at the American Society for Bone and Mineral Research (ASBMR) 27th Annual Meeting. September 29, 2005.
  42. Melton LJ 3rd. Adverse outcomes of osteoporotic fractures in the general population. Bone Mine Res. 2003 Jun;18(6):1139–41.
  43. Miggiano GA, Gagliardi L. [Diet, nutrition and bone health]. Clin Ter. 2005 Jan-Apr;156(1–2):47–56.
  44. Mundy GR. Nutritional modulators of bone remodeling during aging. Am J Clin Nutr. 2006 Feb;83(2):427S–430S.
  45. Nieves JW. Osteoporosis: The role of micronutrients. Am J Clin Nutr. 2005 May;81(5):1232S–1239S.
  46. Okano T. [Vitamin D, K and bone mineral density]. Clin Calcium. 2005 Sep;15(9):1489–94.
  47. Ortolani S, Vai S. Strontium ranelate: An increased bone quality leading to vertebral antifracture efficacy at all stages. Bone. 2006 Feb;38(2 Suppl 1):19–22.
  48. Pennisi P, D’Alcamo MA, et al. Supplementation of L-arginine prevents glucocorticoid-induced reduction of bone growth and bone turnover abnormalities in a growing rat model. J Bone Miner Metab. 2005;23(2):134–9.
  49. Rodriguez JP, Rice S, et al. Modulation of the proliferation and differentiation of human mesenchymal stem cells by copper. J Cell Biochem. 2002;85(1):92–100.
  50. Rossell PA, Parker MJ. Functional outcomes after hip fracture: A one year prospective outcome of 275 patients. Injury. 2003 Jul;34(7):529–32.
  51. Ryder KM, Shorr RI, et al. Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects. J Am Geriatr Soc. 2005 Nov;53(11):1875–80.
  52. Saito N, Nishiyama S. [Aging and magnesium]. Clin Calcium. 2005 Nov;15(11):29–36.
  53. Sasaki S. [Calcium, magnesium, and potassium as dietary nutrients]. Clin Calcium. 2006 Jan;16(1):110–5. Japanese.
  54. Schaafsma A, de Vries PJ, et al. Delay of natural bone loss by higher intakes of specific minerals and vitamins. Crit Rev Food Sci Nutr. 2001 May;41(4):225–49.
  55. Shiraki M, Shiraki Y, et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000 Mar;15(3):515–21.
  56. Spector, T.D. & all. “Effect on bone turnover and BMD of low dose oral silicon as an adjunct to calcium/vitamin D3 in a randomized, placebo-controlled trial.” Presented at the 27th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR). September 2005.
  57. Stone KL, Bauer DC, et al. Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study. J Clin Endocrinol Metab. 2004 Mar;89(3):1217-21.
  58. Takami M, Shinnichi S. [Bone and magnesium]. Clin Calcium. 2005 Nov;15(11):91–6.
  59. Tang, B. & all. ”Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.” The Lancet. Vol. 370. August 25, 2007.
  60. Torricelli P, Fini M, et al. Human osteopenic bone-derived osteoblasts: Essential amino acids treatment effects. Artif Cells Blood Substit Immobil Biotechnol. 2003 Feb;31(1):35–46.
  61. Uebelhart B, Rizzoli R. [Osteoporosis treatment]. Rev Med Suisse. 2006 Jan 4;2(47):47–51.
  62. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–56.
  63. Yamada S, Inaba M. [Osteoporosis and mineral intake]. Clin Calcium. 2004 Dec;14(12):96–9.
  64. Zhang X, Shu XO, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med. 2005 Sep 12;165(16):1890–5.